Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

Michael P. Whyte

doi:10.1002/jbmr.4280

Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

Michael P. Whyte

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	625-626
Number of pages	2
Journal	Journal of Bone and Mineral Research
Volume	36
Issue number	4
DOIs	https://doi.org/10.1002/jbmr.4280
State	Published - Apr 2021

Access to Document

10.1002/jbmr.4280

Cite this

@article{1b982d6773d943768f744040183b877a,

title = "Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody",

author = "Whyte, {Michael P.}",

note = "Funding Information: In this issue of , Jan de Beur and colleagues report the primary analysis and findings up to closure of their prospective, open‐label, single‐arm, phase 2 study (NCT02304367) to evaluate the safety and efficacy of burosumab‐twza for treating adults with a debilitating disorder, tumor‐induced osteomalacia (TIO). Burosumab is the fully human monoclonal antibody against the phosphatonin fibroblast growth factor‐23 (FGF23). Their clinical trial was sponsored and funded by Ultragenyx Pharmaceutical, Inc., in partnership with Kyowa Kirin International, plc (UX023T‐CL201). JBMR ( 1 ) ",

year = "2021",

month = apr,

doi = "10.1002/jbmr.4280",

language = "English",

volume = "36",

pages = "625--626",

journal = "Journal of Bone and Mineral Research",

issn = "0884-0431",

number = "4",

}

TY - JOUR

T1 - Tumor-Induced Osteomalacia

T2 - Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

AU - Whyte, Michael P.

N1 - Funding Information: In this issue of , Jan de Beur and colleagues report the primary analysis and findings up to closure of their prospective, open‐label, single‐arm, phase 2 study (NCT02304367) to evaluate the safety and efficacy of burosumab‐twza for treating adults with a debilitating disorder, tumor‐induced osteomalacia (TIO). Burosumab is the fully human monoclonal antibody against the phosphatonin fibroblast growth factor‐23 (FGF23). Their clinical trial was sponsored and funded by Ultragenyx Pharmaceutical, Inc., in partnership with Kyowa Kirin International, plc (UX023T‐CL201). JBMR ( 1 )

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85102692891&partnerID=8YFLogxK

U2 - 10.1002/jbmr.4280

DO - 10.1002/jbmr.4280

M3 - Editorial

C2 - 33740291

AN - SCOPUS:85102692891

SN - 0884-0431

VL - 36

SP - 625

EP - 626

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

IS - 4

ER -

Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody

Access to Document

Other files and links

Cite this